Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Disetronic shares soar nearly 70% after flotation:

This article was originally published in Clinica

Executive Summary

The newly-floated shares of Swiss company Disetronic rose nearly 70% in the first days of trading on the Zurich stock exchange. The manufacturer of portable drug delivery systems priced its initial public offering at SwFr 1,350 ($1,090) a share and on June 20th, the third day of trading, the shares stood at SwFr 2,250. This values the company, based in Burgdorf, at around SwFr 500 million. The flotation raised SwFr 72 million for Disetronic from the sale of 50,000 newly issued shares. The remaining 22,000 shares were sold by existing stockholders. With a voting stake of 63%, CEO Willy Michel remains in control of the company. After the flotation, shares representing 14% of the vote and 29% of the capital are publicly owned.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT088342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel